Cell Death Dis:维持免疫系统平衡的关键蛋白

2014-05-26 Beyond 生物谷

免疫系统细胞凋亡过程的中断可能导致癌症或免疫缺陷,近日,HZI科学家Ingo Schmitz和他的团队深入探讨免疫系统的细胞凋亡过程。在与Otto von Guericke大学和亥姆霍兹慕尼黑中心研究人员合作,他们阐明了关键性蛋白在细胞凋亡这一过程中的作用。研究结果发表在Cell Death & Disease杂志上,研究发现c-FLIP蛋白能抑制信号级联反应,可导致细胞凋亡。 细胞对病

免疫系统细胞凋亡过程的中断可能导致癌症或免疫缺陷,近日,HZI科学家Ingo Schmitz和他的团队深入探讨免疫系统的细胞凋亡过程。在与Otto von Guericke大学和亥姆霍兹慕尼黑中心研究人员合作,他们阐明了关键性蛋白在细胞凋亡这一过程中的作用。研究结果发表在Cell Death & Disease杂志上,研究发现c-FLIP蛋白能抑制信号级联反应,可导致细胞凋亡。

细胞对病原体的暂时性重要响应,可以确保淋巴细胞(一种类型的免疫细胞),可充分地增殖。到免疫反应的最后,一旦淋巴细胞完成它们的任务,并成功地消除病原体,c-FLIP通常会降低。其结果是,细胞凋亡被再次激活,淋巴细胞死亡,免疫系统的平衡被恢复。

HZI研究人员随后仔细探究蛋白质的特定变体c-FLIPR的确切功能,他们用小鼠进行调查如果这种蛋白质始终存在于淋巴细胞和其他血细胞中会发生什么。研究发现凋亡抑制剂没有造成年轻小鼠异常,但会造成老年小鼠完全不同:淋巴细胞的组成显著改变,Schmitz说:此外,免疫细胞被强烈激活。

过度活化在体内是最明显的,研究人员发现免疫分子--自身抗体,攻击人体肾脏和肺自身组织。此外,他们还发现有害蛋白沉积在肾脏中。在肺组织的变化也表明,在过多c-FLIPR存在情况下,免疫系统攻击其自身身体。免疫细胞会迁移到肺和攻击肺组织,Schmitz说:医生通常会在人类自身免疫性疾病--系统性红斑狼疮患者中看到这些症状。

HZI科学家已经在去年发现如果c-FLIPR永久开启,细胞能更好地对抗细菌感染。这意味着,抑制细胞凋亡在急性感染中有有益作用,但会导致自身免疫反应长期存在。这项研究证实c-FLIPR对免疫系统的平衡是重要的。

原始出处

Ewald F1, Annemann M1, Pils MC2, Plaza-Sirvent C1, Neff F3, Erck C4, Reinhold D5, Schmitz I1.Constitutive expression of murine c-FLIPR causes autoimmunity in aged mice.Cell Death Dis. 2014 Apr 10

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2027600, encodeId=d5d7202e600ae, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Feb 07 10:12:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959071, encodeId=166719590e16d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Sep 17 11:12:00 CST 2014, time=2014-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011890, encodeId=4c3d2011890bf, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 04 19:12:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531381, encodeId=fb541531381d4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Wed May 28 07:12:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868828, encodeId=af37186882895, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 02 09:12:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2027600, encodeId=d5d7202e600ae, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Feb 07 10:12:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959071, encodeId=166719590e16d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Sep 17 11:12:00 CST 2014, time=2014-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011890, encodeId=4c3d2011890bf, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 04 19:12:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531381, encodeId=fb541531381d4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Wed May 28 07:12:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868828, encodeId=af37186882895, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 02 09:12:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]
    2014-09-17 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=2027600, encodeId=d5d7202e600ae, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Feb 07 10:12:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959071, encodeId=166719590e16d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Sep 17 11:12:00 CST 2014, time=2014-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011890, encodeId=4c3d2011890bf, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 04 19:12:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531381, encodeId=fb541531381d4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Wed May 28 07:12:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868828, encodeId=af37186882895, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 02 09:12:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2027600, encodeId=d5d7202e600ae, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Feb 07 10:12:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959071, encodeId=166719590e16d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Sep 17 11:12:00 CST 2014, time=2014-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011890, encodeId=4c3d2011890bf, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 04 19:12:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531381, encodeId=fb541531381d4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Wed May 28 07:12:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868828, encodeId=af37186882895, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 02 09:12:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]
    2014-05-28 cy0328
  5. [GetPortalCommentsPageByObjectIdResponse(id=2027600, encodeId=d5d7202e600ae, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Feb 07 10:12:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959071, encodeId=166719590e16d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Sep 17 11:12:00 CST 2014, time=2014-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011890, encodeId=4c3d2011890bf, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 04 19:12:00 CST 2015, time=2015-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531381, encodeId=fb541531381d4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Wed May 28 07:12:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868828, encodeId=af37186882895, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 02 09:12:00 CST 2014, time=2014-11-02, status=1, ipAttribution=)]

相关资讯

Cell:陈东戎等发现耐药菌抗药“开关”


图片来源:Cell

复旦大学上海医学院英国籍全职***特聘教授、复旦大学生物医学研究院研究员、复旦大学基础医学院教育部分子医学重点实验室教授AlastairMurchie和研究员陈东戎带领的课题组,历经3年多时间,在耐药性病原菌中首次发现了一种对抗氨基糖苷类抗生素药物的新型“核糖开关”,该“开关”对控制此类抗生素的耐药性有重大作用。该成果符合开发新型靶标药物的要求,具有极大的临床实用潜力。1月18日,《细胞》刊发了这一重大发现。

随着抗生素的广泛应用,致病菌的耐药性日益严重,因此找到“耐药性如何形成的新机制”已成为各国科学家面临的共同难题。该课题组此次发现耐药菌对抗氨基糖苷类抗生素药物的新型“核糖开关”,有望攻克此类药物带来的耐药难题。以卡那霉素、链霉素、庆大霉素和新霉素等为代表的氨

Nature:白介素-35 (IL-35)的负免疫调控作用

这项研究发现,产生白介素-35 (IL-35)的B细胞是新颖的负免疫调控因子。具有不能产生IL-35 的B细胞的小鼠被证明易患诱导的自免疫疾病,同时对沙门氏菌感染的抵抗力增强。这一发现表明,IL-35 由B细胞的生成是自免疫疾病和传染病的一个潜在治疗目标。原始出处:Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg

PNAS:肠道微生物群信号可能调控血压

一项研究发现,通过对两个主要的短链脂肪酸(SCFAs)受体——嗅觉受体78 (Olfr78)和Gpr41起作用,肠道微生物群产生的短链脂肪酸(SCFAs)可能在调控血压方面起到作用。 Jennifer L. Pluznick及其同事发现,Olfr78在肾脏中表达,并且会响应短链脂肪酸(SCFAs),特别是响应丙酸盐,而介导肾素分泌。当给小鼠提供丙酸盐的时候,它们的血压会出现幅度大而迅速的基于剂量

PLoS Comput Biol:科学家开发出研究丙肝病毒传播的新方法

近日,刊登在国际杂志PLoS Computational Biology上的一篇研究报告中,来自牛津大学的研究者表示,对静脉注射感染丙肝的患者进行早期诊断和相应的疗法可以有效抑制丙肝病毒的多次传播。 研究者Gkikas Magiorkinis说,这项研究中我们首次揭示了丙肝病毒之所以具有超级传播性是由于进行静脉注射药物的人所引发的。我们希望可以扩大对静脉注射药物个体的早期诊断和抗病毒的治疗,从而

Science:研究者或可构建一种更好的HIV疫苗

刊登在近日的国际杂志Science上的一篇研究报告中,来自国外的研究人员设计了一种免疫原,它代表了朝着制造一种可在人体内释放对抗HIV-1的广谱中和抗体疫苗所迈出的重要的第一步。 Joseph Jardine及其同事对近些年来在世界各地的病人体内分离出的这种高度有效的广谱中和抗体——它对HIV-1的gp120包膜蛋白具有特异性——进行了研究。 研究人员接着想出了一种方法来设计可与这些高度变异的

研究称英国30多年后炎热发病致死人数倍增

全球变暖正给人们的健康带来不利影响。英国的一项新研究称,到2050年,因炎热导致发病死亡的英国人将增加两倍多,其中老年人面临的“热病”风险最高。 英国英格兰公共卫生局等机构研究人员在英国新一期《流行病和公共卫生杂志》上报告说,他们对1993年至2006年间英国的天气情况和死亡率进行了研究,重点分析气温变化与相关疾病发病之间的关系。 结果显示,照目前的全球变暖和人口增加趋势,到2020年,英国因